We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genus Plc | LSE:GNS | London | Ordinary Share | GB0002074580 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 84.00 | 4.71% | 1,868.00 | 1,854.00 | 1,860.00 | 1,872.00 | 1,776.00 | 1,776.00 | 80,575 | 16:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 689.7M | 33.3M | 0.5043 | 36.84 | 1.23B |
From May 2019 to May 2024
TIDMGNS
RNS Number : 9125R
Genus PLC
20 June 2018
For Immediate Release 20 June 2018
Genus plc
('Genus', the 'Company' or the 'Group')
Capital Markets Event
Genus, a leading global animal genetics company, is holding a Capital Markets Event today at 2pm at which no material new information will be disclosed and Genus will not be commenting on current trading.
The Capital Markets Event will cover Genus's business model and the initiatives being implemented to further strengthen its leadership in the animal genetics market. The presentations given by Genus's management will be made available on the Company website tomorrow.
For further information please contact:
Genus plc Tel: 01256 345970 Karim Bitar, Chief Executive Stephen Wilson, Group Finance Director Buchanan Tel: 0207 466 5000 Charles Ryland/ Chris Lane/ Sophie Wills
This announcement will be available on the Genus website, www.genusplc.com
About Genus
Genus is a world-leading animal genetics company. We continuously produce better breeding livestock with desirable characteristics, which helps farmers to produce better quality meat and milk more efficiently and sustainably. We do this by analysing animals' DNA to select those with desirable characteristics, and then breed successive generations from those animals. We also own technology to screen and process semen for desirable traits, such as gender, and license technology to make precise, desirable gene edits to animals' DNA.
Genus's worldwide sales are made in over seventy countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in production.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, proprietary technology and knowhow used to improve them, relationships with leading meat and milk producers, and its global supply chain and distribution networks.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCBUGDLRUBBGIC
(END) Dow Jones Newswires
June 20, 2018 02:00 ET (06:00 GMT)
1 Year Genus Chart |
1 Month Genus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
